International Assets Investment Management LLC Invests $11.26 Million in Exact Sciences Co. (NASDAQ:EXAS)

International Assets Investment Management LLC purchased a new position in Exact Sciences Co. (NASDAQ:EXAS) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 165,259 shares of the medical research company’s stock, valued at approximately $11,257,000. International Assets Investment Management LLC owned about 0.09% of Exact Sciences at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Itau Unibanco Holding S.A. purchased a new position in shares of Exact Sciences in the 2nd quarter worth about $29,000. V Square Quantitative Management LLC purchased a new position in shares of Exact Sciences in the 3rd quarter worth about $47,000. EverSource Wealth Advisors LLC raised its position in Exact Sciences by 92.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 708 shares of the medical research company’s stock worth $49,000 after buying an additional 340 shares during the last quarter. GAMMA Investing LLC raised its position in Exact Sciences by 48.4% in the 2nd quarter. GAMMA Investing LLC now owns 1,362 shares of the medical research company’s stock worth $58,000 after buying an additional 444 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new position in Exact Sciences in the 1st quarter worth about $67,000. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In related news, EVP Brian Baranick sold 929 shares of the business’s stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.36% of the stock is currently owned by corporate insiders.

Exact Sciences Trading Up 1.2 %

Shares of NASDAQ:EXAS opened at $70.46 on Thursday. The stock has a 50 day moving average of $66.41 and a 200 day moving average of $56.52. The company has a market cap of $13.00 billion, a PE ratio of -53.38 and a beta of 1.27. The company has a current ratio of 2.17, a quick ratio of 1.98 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. The company had revenue of $699.26 million during the quarter, compared to the consensus estimate of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm’s revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.45) EPS. As a group, equities research analysts expect that Exact Sciences Co. will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a research report on Thursday, September 26th. The Goldman Sachs Group decreased their target price on Exact Sciences from $88.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, July 17th. Benchmark decreased their target price on Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Stifel Nicolaus decreased their target price on Exact Sciences from $100.00 to $82.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Finally, Sanford C. Bernstein boosted their target price on Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, Exact Sciences has a consensus rating of “Moderate Buy” and an average price target of $80.64.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.